N/A
N=82
Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region
Lax Skin
Bottom Line
View on ClinicalTrials.gov: NCT04146467 ↗Enrolled (actual)
82
Serious AEs
3.7%
Results posted
Jul 2022
Primary outcome: Primary: Day 180 Number of Participants With Improvement Measured By Independent Photographic Review — 6; 52 Participants — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Renuvion APR Device (Device)
- Age
- Adult, Older Adult · 35+ yrs
- Sex
- All
- Sponsor
- Apyx Medical
- Primary completion
- Feb 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Day 180 Number of Participants With Improvement Measured By Independent Photographic Review |
6; 52 | <0.0001 sig |
| PRIMARY Subject Reported Pain - None to Moderate |
13; 62 | — |
Summary
This is a prospective, multi-center, multi-phase, evaluator-blinded study of subjects undergoing a procedure with the Renuvion APR Device to improve the appearance of lax tissue in the neck and submental region.
Eligibility Criteria
Inclusion Criteria
- Male or female subjects 35-65 years of age (inclusive).
- Healthy as determined by the investigator examining the subject.
- Seeking improvement of the appearance of lax tissue in the neck and submental region.
- Females of childbearing potential who are sexually active must be willing to use an approved method of birth control during study participation.
- Willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits.
- Willing to release rights for the use of study photos, including in potential publication.
- Understands and accepts the obligation not to have significant weight loss or weight gain (≥8 pounds) post the treatment, and for the duration of participation in the study.
- Willing to abstain from the use of blood thinners (including, but not limited to, Coumadin, NSAIDS, Ibuprofen, vitamin K, other) for 2 weeks (14 days) prior to the procedure.
- Willing to abstain from smoking, vaping, or the use of e-cigarettes for 1 year prior to and for the entire duration of participation in the study.
- Willing to abstain from the use of marijuana for 2 weeks prior to and for the duration of participation in the study.
- Able to read, understand, sign and date the informed consent document (English only).
Exclusion Criteria
- Pregnant or lactating.
- Pregnancy within 12 months prior to screening.
- Use within 24 hours preceding surgery of ibuprofen, acetaminophen, any other analgesics, anti-inflammatory products, or any products including herbals and supplements that could interfere with the clinical assessments of this study (other than drugs used for anesthesia).
- Allergy to tumescent anesthetic (lidocaine/epinephrine).
- Excessive subcutaneous fat in the treatment area (as determined by the treating investigator).
- Active systemic or local skin disease that may alter wound healing.
- Significant or uncontrolled medical condition that, in the opinion of the investigator, participation in the study may compromise the patient's health.
- Severe solar elastosis.
- History of autoimmune disease (excluding Hashimoto's thyroiditis).
- Known hypersensitivity or adverse reaction to anesthetics.
- Known susceptibility to keloid formation or hypertrophic scarring.
- Cancerous or pre-cancerous lesions in the area to be treated.
- History or current diagnosis of cancer of any type (excluding skin cancer).
- History of uncontrolled cardiovascular disease (i.e. myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other).
- History, or current bleeding disorders (i.e. hemophilia or von Willebrand disease), or anticipated treatment with prescription anticoagulants.
- Possesses a surgically implanted electronic device (i.e. pacemaker).
- History of AIDs/HIV.
- Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years.
- Chronic hypoxia or dependence on supplemental oxygen.
- Participation in any other investigational study within 30 days prior to consent.
- Any surgical or transdermal neck/submental aesthetic procedures or plans to undergo any other aesthetic procedure during study participation. Such procedures include, but are not limited to, submentoplasty, liposuction, ultrasound, cryolipolysis, radiofrequency, and laser.
- History of or current injury to the head and neck or any area of the body being treated as a part of this study.
- Presence of more than mild platysmal banding as per the Geister, et al Validated Assessment Scale for Platysmal Bands.
- Subject requiring removal of adipose tissue prior index procedure.
- A family member of the investigator or sponsor; an employee of the investigator or sponsor.
- Subject who, in the opinion of the investigator, is not an appropriate candidate for the study.
Data sourced from ClinicalTrials.gov (NCT04146467). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.